Application of drug combination of vitamin K1 and temozolomide in preparation of medicine for treating cholangiocarcinoma

A technology of temozolomide and combined medication, which is applied in the field of medicine, can solve the problems that have not been reported yet, and achieve the effects of improving anti-tumor effect, reducing dosage, and reducing toxic and side effects

Inactive Publication Date: 2021-05-28
阿耳法猫(杭州)人工智能生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There are no reports on the combined effects of vitamin K1 and temozolomide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of drug combination of vitamin K1 and temozolomide in preparation of medicine for treating cholangiocarcinoma
  • Application of drug combination of vitamin K1 and temozolomide in preparation of medicine for treating cholangiocarcinoma
  • Application of drug combination of vitamin K1 and temozolomide in preparation of medicine for treating cholangiocarcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Detection of the sensitivity of different cholangiocarcinoma cells to vitamin K1 by MTT method

[0024] 1. Experimental materials

[0025] (1) Drugs: vitamin K1 injection.

[0026] (2) Cholangiocarcinoma cells: human cholangiocarcinoma cells CCLP cells and HUCCT1 cells.

[0027] (3) A commercially available MTT kit.

[0028] 2. Experimental grouping

[0029] (1) Control group: blank control, that is, cholangiocarcinoma cells were not treated with any drug.

[0030] (2) Experimental group: cholangiocarcinoma cells were treated with different concentrations of vitamin K1.

[0031] 3. MTT assay to detect the sensitivity of different tumor cells to vitamin K1

[0032] (1) Human cholangiocarcinoma cell CCLP cells and HUCCT1 cells were seeded into 96-well plates at a number of 5000-9000 cells per well. After the cells adhered, PBS solutions of different concentrations of vitamin K1 were added respectively. After culturing for 24 hours, 10 μl of MTT at a concen...

Embodiment 2

[0034] Example 2 The effect of temozolomide alone or the combination of vitamin K1 and temozolomide on the inhibition rate of cholangiocarcinoma cells

[0035] 1. Experimental materials

[0036] (1) Drugs: vitamin K1 injection, temozolomide.

[0037] (2) Cholangiocarcinoma cells: human cholangiocarcinoma cells CCLP cells and HUCCT1 cells.

[0038] (3) A commercially available MTT kit.

[0039] 2. Experimental grouping

[0040] (1) Control group: Cholangiocarcinoma cells were treated with temozolomide only.

[0041] (2) Experimental group: Combined use of different concentrations of vitamin K1 and temozolomide to treat cholangiocarcinoma cells.

[0042] 3. MTT assay to detect the sensitivity of cholangiocarcinoma cells to the combination of vitamin K1 and temozolomide

[0043] (1) The human cholangiocarcinoma cells CCLP cells and HUCCT1 cells were seeded into 96-well plates at the number of 5000-9000 cells per well. After the cells adhered, PBS solutions with different rat...

Embodiment 3

[0045] Example 3 The effect of temozolomide alone or the combination of vitamin K1 and temozolomide on the inhibition rate of human cholangiocarcinoma tissue organoids

[0046] 1. Experimental materials

[0047] (1) Drugs: vitamin K1 injection, temozolomide.

[0048] (2) Cholangiocarcinoma cells: human cholangiocarcinoma tissue organoids.

[0049] (3) Commercially available CellTiter-Glo 3D kit.

[0050] 2. Experimental grouping

[0051] (1) Control group: only treated with temozolomide.

[0052] (2) Experimental group: different concentrations of vitamin K1 and temozolomide were used in combination to treat human cholangiocarcinoma tissue organoids.

[0053] 3. Sensitivity of human cholangiocarcinoma tissue organoids to the combination of vitamin K1 and temozolomide

[0054] (1) Mix the treated human cholangiocarcinoma cells with Matrigel, add 50 μl of mixed Mtrigel Matrigel to each well on a 48-well plate, add 250 μl of complete medium to each well after gel formation, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine, and particularly relates to application of a drug combination of vitamin K1 and temozolomide in preparation of a medicine for treating bile duct cancer. The application of the drug combination of the vitamin K1 and the temozolomide in preparation of the medicine for treating the cholangiocarcinoma is provided for the first time, the vitamin K1 and the temozolomide have an obvious synergistic effect, so curative effect is effectively improved; the curative effect of the drug combination is more obvious compared with a single component, and killing performance on tumor cells is improved; dosage is effectively reduced, so toxic and side effects are reduced; and the drug combination can save cost, relieve the economic burden of patients, provide a new way for the prevention and treatment of bile duct cancer, and have wide application prospects in the field of medicine and pharmacology.

Description

technical field [0001] The invention belongs to the field of medicine, and particularly relates to the application of vitamin K1 and temozolomide in combination in preparing a medicine for treating cholangiocarcinoma. Background technique [0002] Cholangiocarcinoma is a malignant tumor originating from bile duct epithelial cells and is the second most common malignant tumor of the hepatobiliary system after liver cancer. The overall mortality of hepatobiliary malignancies ranks fifth among all malignant tumors. my country is a high-incidence area of ​​cholangiocarcinoma, and the incidence has been increasing in recent years. Cholangiocarcinoma is highly aggressive, only 30% to 40% of patients can be effectively treated by surgical resection at the time of diagnosis, while most patients are diagnosed at an advanced stage, lacking effective treatment methods, and the prognosis is extremely poor. [0003] Temozolomide is a first-line chemotherapeutic drug against malignant g...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61K31/4188A61P35/00
CPCA61K31/122A61K31/4188A61P35/00A61K2300/00
Inventor 李斌
Owner 阿耳法猫(杭州)人工智能生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap